美国医生对同时使用苯二氮䓬类药物的高风险患者开具新阿片处方的趋势
该研究利用2005至2015年美国门诊医疗调查数据,分析成人新阿片处方与同时使用苯二氮䓬类药物的关系。结果显示,同时使用苯二氮䓬类药物的患者新阿片处方率从2005年189/1000升至2010年351/1000,后降至2015年172/1000;调整后相对风险为1.83。纳洛酮共用处方率不足1%。
要点
- 同时使用苯二氮䓬类药物的患者新阿片处方率在2010年前上升,之后下降。
- 调整人口学、合并症和疼痛诊断后,该类患者获得新阿片处方的相对风险为1.83。
- 纳洛酮共用处方率低于1%,提示改善高风险患者疼痛治疗质量的机会。
核心结论
- 2010年后高风险患者新阿片处方率下降,提示近期阿片相关死亡增加可能与医生开具新阿片处方之外的因素有关。
- 但高风险患者的新阿片处方率仍高于一般人群,是改善疼痛治疗质量的重要机会。
研究设计与样本
- 研究对象为20岁及以上接受新阿片处方并同时使用苯二氮䓬类药物的成人。
主要发现
- 当患者同时使用苯二氮䓬类药物时,纳洛酮共用处方率低于1%。
关键数值与推荐
- 同时使用苯二氮䓬类药物的成人新阿片处方率:2005年189/1000人,2010年351/1000人,2015年172/1000人。
- 一般人群新阿片处方率:2005年78/1000人,2010年93/1000人,2015年79/1000人。
- 纳洛酮共用处方率低于1%。
临床怎么用
- 临床医生应为同时使用苯二氮䓬类药物的疼痛患者谨慎评估新阿片处方的风险与获益。
- 对此类高风险患者应考虑纳洛酮共用处方,尽管原文显示实际共用处方率低于1%。
- 需关注高风险患者的新阿片处方率仍高于一般人群,以改善疼痛治疗质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent increases in US opioid-related deaths underscore the need to understand drivers of fatal overdose. The initial prescription of opioids represents a critical juncture because it increases the risk of future opioid use disorder and is preventable. OBJECTIVE: To examine new opioid prescribing patterns in US patients at increased risk of overdose from benzodiazepine use. DESIGN, SETTING, AND PARTICIPANTS: This study used publicly available data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey from January 1, 2005, through December 31, 2015, to identify adults 20 years or older receiving new opioid prescriptions and concurrently using a benzodiazepine. MAIN OUTCOMES AND MEASURES: Population-based rates of new opioid prescriptions stratified by use of benzodiazepines. RESULTS: This study analyzed 13 146 visits, representing 214 million visits nationally, with a new opioid prescription. Rates of new opioid prescriptions among adults using a benzodiazepine increased from 189 to 351 per 1000 persons between 2005 and 2010 (rate difference, 162; 95% CI, 29-295; P = .02) and decreased to 172 per 1000 persons by 2015 (rate difference, -179; 95% CI, -310 to -48; P = .008). New opioid prescriptions in the general population not using benzodiazepines increased nonsignificantly from 78 to 93 per 1000 US persons between 2005 and 2010 (rate difference, 15; 95% CI, -3 to 33; P = .10) and decreased nonsignificantly to 79 per 1000 persons by 2015 (rate difference, -14; 95% CI, -38 to 11; P = .28). The likelihood of receiving a new opioid prescription during an ambulatory visit remained higher for patients concurrently using benzodiazepines compared with the general population after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain (adjusted relative risk, 1.83; 95% CI, 1.56-2.15; P < .001). Naloxone was coprescribed in less than 1% of visits when a patient concurrently used a benzodiazepine. CONCLUSIONS AND RELEVANCE: In 2010, new opioid prescriptions for US adults stopped increasing and began to decrease among higher-risk patients who used benzodiazepines. These patterns suggest that the recent increase in opioid-related deaths may be associated with factors other than physicians writing new opioid prescriptions. Nevertheless, prescribing among higher-risk patients still occurred at rates higher than rates in the general population, representing an important opportunity to improve quality of care for patients experiencing pain.
引用
- Ladapo JA, Larochelle MR, Chen A, et al. Physician Prescribing of Opioids to Patients at Increased Risk of Overdose From Benzodiazepine Use in the United States. JAMA Psychiatry. 2018. PMID: 29710086. doi:10.1001/jamapsychiatry.2018.0544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。